Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek C Goodoory

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Alimentary Pharmacology & Therapeutics|August 8, 2022
Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome. Authors' replyVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|May 2, 2022
Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United KingdomVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|February 15, 2022
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndromeVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|April 24, 2023
Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' replyVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|June 12, 2023
Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome-authors' replyVivek C Goodoory, Cho E Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|May 25, 2022
Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Authors' replyVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|March 14, 2023
Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndromeVivek C Goodoory, Cho E Ng, Christopher J Black, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 1, 2023
Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel SyndromeVivek C Goodoory, Ashok K Tuteja, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|October 28, 2024
Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary CareVivek C Goodoory, Christy Riggott, Mais Khasawneh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 6, 2021
Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up StudyVivek C Goodoory, Lesley A Houghton, Yan Yiannakou, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Alimentary Pharmacology & Therapeutics|August 8, 2022
Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome. Authors' replyVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|May 2, 2022
Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United KingdomVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|February 15, 2022
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndromeVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|April 24, 2023
Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' replyVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|June 12, 2023
Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome-authors' replyVivek C Goodoory, Cho E Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|May 25, 2022
Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Authors' replyVivek C Goodoory, Cho Ee Ng, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|March 14, 2023
Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndromeVivek C Goodoory, Cho E Ng, Christopher J Black, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 1, 2023
Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel SyndromeVivek C Goodoory, Ashok K Tuteja, Christopher J Black, et al.
Alimentary Pharmacology & Therapeutics|October 28, 2024
Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary CareVivek C Goodoory, Christy Riggott, Mais Khasawneh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 6, 2021
Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up StudyVivek C Goodoory, Lesley A Houghton, Yan Yiannakou, et al.
Pageof 4